Cutaneous Melanoma Clinical Trials

18 studies are recruiting for cutaneous melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sylvester Comprehensive Cancer Center - Miami, Miami, Florida

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

3. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

   This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Presbyterian/St Lukes Medical Center, Denver, Colorado

   Locations

   15 in total

   Run by

   Pfizer

   See if you can join NCT07519655 on ClinicalTrials.gov

4. A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

   This clinical trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors that have not spread to other parts of the body (localized). Melanoma is …

   Stage

   Not phased

   Ages

   Up to 25

   Site

   Kaiser Permanente-Oakland, Oakland, California

   Locations

   5 in total

   Run by

   Children's Oncology Group

   See if you can join NCT07621614 on ClinicalTrials.gov

5. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Medical Center, Los Angeles, California

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

6. Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

   This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge gained from this study may be used to guide the design of prospective clinical trials of lifestyle i…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04778449 on ClinicalTrials.gov

7. A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

   The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will comp…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   USC Newport Beach, Newport Beach, California

   Locations

   9 in total

   Run by

   Linnaeus Therapeutics, Inc.

   See if you can join NCT06624644 on ClinicalTrials.gov

8. EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

   This phase II trial tests how well EMLA topical cream works in treating pain in patients with skin cancers receiving Technetium 99 injections for a lymphoscintigraphy mapping procedure. A lymphoscintigraphy mapping procedure is used to find the main or lead lymph node (tissue that fight infection) …

   Stage

   Phase 2

   Ages

   18 to 99

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT06223659 on ClinicalTrials.gov

9. Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

   This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment stra…

   Stage

   Not phased

   Ages

   Any age

   Site

   The Ohio State University Wexner Medical Center, Columbus, Ohio

   Run by

   Mohamed Abdel-Rahman

   See if you can join NCT04792463 on ClinicalTrials.gov

10. ACTengine® IMA203 Combined With mRNA-4203

    This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    4 in total

    Run by

    Immatics US, Inc.

    See if you can join NCT06946225 on ClinicalTrials.gov

11. Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

    The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combination with mutant BRAF inhibitors or after BRAF/MEK inhibito…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Iowa, Iowa City, Iowa

    Locations

    2 in total

    Run by

    University of Utah

    See if you can join NCT06194929 on ClinicalTrials.gov

12. Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

    The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT07148245 on ClinicalTrials.gov

13. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

14. A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

    KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA Health, Los Angeles, California

    Locations

    15 in total

    Run by

    Krystal Biotech, Inc.

    See if you can join NCT05970497 on ClinicalTrials.gov

15. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    13 in total

    Run by

    GV20 Therapeutics

    See if you can join NCT05669430 on ClinicalTrials.gov

16. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

    This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Austin, Austin, Texas

    Locations

    4 in total

    Run by

    OncoResponse, Inc.

    See if you can join NCT06090266 on ClinicalTrials.gov

17. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Scottsdale, Arizona

    Locations

    11 in total

    Run by

    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov

18. Neoadjuvant Combination Immunotherapy for Stage III Melanoma

    Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Louisville, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT03842943 on ClinicalTrials.gov